-- Investment Will Provide BioAgilytix with Additional Resources to Invest 
     in Core Business and Drive Growth

BioAgilytix, a leading global contract research organization (CRO), today 
announced an agreement to be further capitalized by Cinven, a leading 
international private investment firm focused on building world-class global 
companies. Cinven will acquire a majority stake in BioAgilytix while current 
majority investor Cobepa, S.A., a Brussels-based private investment firm, will 
remain a significant minority investor in the Company.

Logo - https://mma.prnewswire.com/media/1690414/BioAgilytix_Cinven_Logo.jpg 

Cobepa and GHO Capital, a leading specialist investor in global healthcare, 
acquired BioAgilytix in November of 2018 and have built the company into a 
recognized global leader in the contract research organization market with a 
focus on large molecule bioanalytical testing. The investment by Cinven will 
provide BioAgilytix with increased funding and resources to meet the growing 
demand for its high-quality bioanalytical services, driven by its strong 
scientific reputation and leading expertise in supporting the development and 
commercialization of novel therapeutics.

"Our focus on providing customers with industry leading scientific expertise 
coupled with superior service across the pharmaceutical development pathway has 
been our formula for success," said Jim Datin, President and CEO of 
BioAgilytix. "As we move into our next chapter of our evolution, Cinven will 
provide the additional resources that will empower us to expand not only our 
geographical reach but will also enable us to invest further in our talent and 
facilities around the globe to meet the ever-growing needs of our customers."

Peter Connolly, Managing Director and Head of North America of Cobepa said, "We 
are excited to continue working with Jim and the entire BioAgilytix management 
team and are thrilled to welcome Cinven as a new investor in the Company. The 
success of BioAgilytix is driven by its unwavering focus on both high-quality 
science and a customer-first orientation. These are exactly the hallmarks we 
seek in our investments. We look forward to partnering with Cinven and 
management for the next chapter of the Company's growth."

Mike Mortimer, Managing Partner at GHO Capital said, "BioAgilytix is now a 
leading innovator among the global CROs. Throughout our partnership, Jim and 
his team have had a phenomenal impact to drive international growth, invest 
significantly in operational capacity and expand the platform's capabilities to 
provide more and better solutions to customers. With a science and quality led, 
customer-centric approach, we have every confidence they will continue to 
deliver breakthrough solutions to global biopharma, supporting the safe & 
effective discovery and development of new biologic drugs to improve patient 
outcomes for years to come."

Alex Leslie, Partner, Healthcare and Head of US said, "Cinven is delighted to 
be making this investment into BioAgilytix. The organization has genuine 
expertise and differentiated capabilities in the attractive bioanalytical 
testing market, providing excellent service to numerous pharma and biotech 
customers. Cinven plans to support the highly skilled management and scientific 
leadership teams to invest in capacity and capabilities to capture the 
compelling growth opportunity in the market, ultimately supporting the delivery 
of new therapies for patients globally. We look forward to working with the 
entire BioAgilytix team to help them to realise the full potential in the 
business."

BofA Securities served as lead financial advisor to BioAgilytix, and William 
Blair and Lazard served as co-advisors. White & Case served as legal advisor 
and Deloitte LLP as accounting and tax advisor to BioAgilytix. Ropes & Gray 
acted as legal advisor to GHO with Deloitte LLP serving as tax advisor.

The transaction is expected to close after customary closing conditions and 
regulatory approvals.

About BioAgilytix

BioAgilytix is a leading global contract research organization focused on 
supporting pharmaceutical and biotech partners in all phases of drug 
development. With laboratory locations in North Carolina's Research Triangle 
Park; Cambridge, Massachusetts; San Diego, California; Melbourne and Brisbane, 
Australia and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, 
biomarkers, and cell-based assay services supporting the development and 
release testing of therapeutics across a number of industries and disease 
states.

BioAgilytix offers assay development, validation, and sample analysis under 
non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product 
release testing, stability testing, etc.) BioAgilytix also offers diagnostic 
testing services at its CLIA-certified, CAP-accredited Boston laboratory.

BioAgilytix's team of highly experienced scientific and QA professionals 
ensures high-quality science, data integrity and regulatory compliance through 
all phases of clinical development. BioAgilytix is a trusted partner to many 
top global pharmaceutical and biotech companies. For more information, visit 
www.bioagilytix.com.

About Cinven

Cinven is a leading international private equity firm focused on building 
world-class global companies. Its funds invest in six key sectors: Business 
Services, Consumer, Financial Services, Healthcare, Industrials and Technology, 
Media and Telecommunications (TMT). Cinven has offices in London, Frankfurt, 
Paris, Milan, Madrid, New York, Guernsey and Luxembourg.

Cinven takes a responsible approach towards its portfolio companies, their 
employees, suppliers, local communities, the environment and society.
Cinven Capital Management (V) General Partner Limited, Cinven Capital 
Management (VI) General Partner Limited, Cinven Capital Management (VII) 
General Partner Limited and Cinven Capital Management (SFF) General Partner 
Limited are each authorised and regulated by the Guernsey Financial Services 
Commission, and Cinven Limited, the adviser to the Cinven Funds, is authorised 
and regulated by the Financial Conduct Authority.

In this press release 'Cinven' means, depending on the context, any of or 
collectively, Cinven Holdings Guernsey Limited, Cinven Partnership LLP, Cinven 
(LuxCo1) S. ὰ.r.l., and their respective Associates (as defined in the 
Companies Act 2006) and/or funds managed or advised by any of the foregoing.

For additional information on Cinven please visit www.cinven.com and 
www.linkedin.com/company/cinven/. 

About Cobepa

Based in Brussels, New York, and Munich, Cobepa is a privately-held investment 
company backed by European families. Cobepa manages a diversified portfolio of 
private equity investments valued at approximately $4 billion. Cobepa invests 
in leading companies with superior business models, sustainable market 
positions and leading management teams. Cobepa North America is primarily 
focused on investments in the healthcare, business services, and tech-enabled 
services sectors as well as situations which might benefit from a nimble 
investment partner. For more information, visit www.cobepa.com.

About GHO Capital 

Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading 
specialist healthcare investment advisor based in London. We apply global 
capabilities and perspectives to unlock high growth healthcare opportunities, 
targeting Pan-European and transatlantic internationalization to build market 
leading businesses of strategic global value. Our proven investment track 
record reflects the unrivalled depth of our industry expertise and network. We 
partner with strong management teams to generate long-term sustainable value, 
improving the efficiency of healthcare delivery to enable better, faster, more 
accessible healthcare. For further information, please visit www.ghocapital.com

Media Contact:
Mark Bethers
BioAgilytix
919-381-6097
mark.bethers@bioagilytix.com

Source - BioAgilytix